Jessica Mendoza

The old Lars, Lars Sorensen, was actually Lars Jørgensen's predecessor. Sorensen was CEO at the time when Novo was just beginning to set the stage for its GLP-1 success. Now, he'll be returning to oversee the company's future.

Novo Nordisk says it won't be changing its strategy, despite the shakeups at the top. Thank you.

Novo Nordisk says it won't be changing its strategy, despite the shakeups at the top. Thank you.

Novo Nordisk says it won't be changing its strategy, despite the shakeups at the top. Thank you.

Well, thank you for being here and being so patient with all of our tech stuff. Last year, I interviewed Lars Sorensen, the returning Lars, for our series Trillion Dollar Shot, which is about the rise of GLP-1 drugs. At the time, I asked him about Novo's rivalry with Eli Lilly. Who would you say is winning the competition right now?

Well, thank you for being here and being so patient with all of our tech stuff. Last year, I interviewed Lars Sorensen, the returning Lars, for our series Trillion Dollar Shot, which is about the rise of GLP-1 drugs. At the time, I asked him about Novo's rivalry with Eli Lilly. Who would you say is winning the competition right now?

Well, thank you for being here and being so patient with all of our tech stuff. Last year, I interviewed Lars Sorensen, the returning Lars, for our series Trillion Dollar Shot, which is about the rise of GLP-1 drugs. At the time, I asked him about Novo's rivalry with Eli Lilly. Who would you say is winning the competition right now?

Sorensen told me he had the highest respect for Eli Lilly and that they keep each other on their toes.

Sorensen told me he had the highest respect for Eli Lilly and that they keep each other on their toes.

Sorensen told me he had the highest respect for Eli Lilly and that they keep each other on their toes.

Yeah.

Yeah.

Yeah.

We asked the foundation yesterday if Sorensen still welcomes the competition. The foundation had no further comment. In the meantime, both Novo and Lilly are pressing on with the next big thing. Promises of more effective injectables, a more convenient pill, and even more weight loss.

We asked the foundation yesterday if Sorensen still welcomes the competition. The foundation had no further comment. In the meantime, both Novo and Lilly are pressing on with the next big thing. Promises of more effective injectables, a more convenient pill, and even more weight loss.

We asked the foundation yesterday if Sorensen still welcomes the competition. The foundation had no further comment. In the meantime, both Novo and Lilly are pressing on with the next big thing. Promises of more effective injectables, a more convenient pill, and even more weight loss.

What does this leadership shakeup sort of say about the pharmaceutical industry right now, like especially in the weight loss space?

What does this leadership shakeup sort of say about the pharmaceutical industry right now, like especially in the weight loss space?

What does this leadership shakeup sort of say about the pharmaceutical industry right now, like especially in the weight loss space?

Right.